Myopia
Myopia, also named near-sightedness and short-sightedness, is a common eye disease in which image of distant objects focuses in front of retina. As the result, the vision pattern is clear vision of close objects, but blurry vision of far objects. Myopia usually develops during childhood and adolescence. Then, it becomes stable between the ages of 20 and 40. Globally, the prevalence of myopia is nearly 2 billion people (more than 28.3% of the global population) and is growing rapidly, projected to reach 4.76 billion (49.8% of the global population) in 2050, while the prevalence of high myopia is expected to rise from the current 4.0% to 9.8%, nearly 1 billion people[1]. In East Asia and parts of South-East Asia, the prevalence of both myopia and high myopia was high (47.0%), much higher than Central Europe (27.1%), Central Asia (17.0%), and Central Africa (7.0%)[2].
Besides the main symptom, myopia also exhibits other symptoms, including headaches, eyestrain, and squint or partially close the eyelids to see clearly. Severe myopia, increased risk of retinal detachment, glaucoma, cataracts, and other serious eye pathologies. Normally, a basic eye exam can confirm myopia. And a series of exam schedule could monitor myopia progression and other complications. Current medical corrections are quite limited, such as the eyeglasses, contact lenses or refractive surgery. However, the efficacy and safety among the above are unsatisfactory.
The novel ophthalmic medicine treatment (low-dose atropine sulfate eye drops) is the only drug verified by evidence-based medicine to effectively delay the progression of myopia of children and adolescents.
OS001
OS001 is 0.01% and 0.02% atropine sulfate eye drops in our innovative pipeline for delaying the myopia progression of children and adolescents. As the optimal concentrations, OS001 achieves a superior comprehensive clinical benefit with minimized side effects. Acceleration and long-term stability data prove the superior stability of OS001 under multiple temperature and humidity circumstances.
Reference
[1] Expert Consensus on Prevention and Control of High Myopia (2023).
[2] Paul N. Baird, Seang-Mei Saw, Carla Lanca, et al. Myopia. PRIMER. (2020) 6:99.
Seefunge Pharmaceutical Technology Co., Ltd.
Address: BioPharma Town, Hangzhou City, Zhejiang Province, China
Myopia
Myopia, also named near-sightedness and short-sightedness, is a common eye disease in which image of distant objects focuses in front of retina. As the result, the vision pattern is clear vision of close objects, but blurry vision of far objects. Myopia usually develops during childhood and adolescence. Then, it becomes stable between the ages of 20 and 40. Globally, the prevalence of myopia is nearly 2 billion people (more than 28.3% of the global population) and is growing rapidly, projected to reach 4.76 billion (49.8% of the global population) in 2050, while the prevalence of high myopia is expected to rise from the current 4.0% to 9.8%, nearly 1 billion people[1]. In East Asia and parts of South-East Asia, the prevalence of both myopia and high myopia was high (47.0%), much higher than Central Europe (27.1%), Central Asia (17.0%), and Central Africa (7.0%)[2].
Besides the main symptom, myopia also exhibits other symptoms, including headaches, eyestrain, and squint or partially close the eyelids to see clearly. Severe myopia, increased risk of retinal detachment, glaucoma, cataracts, and other serious eye pathologies. Normally, a basic eye exam can confirm myopia. And a series of exam schedule could monitor myopia progression and other complications. Current medical corrections are quite limited, such as the eyeglasses, contact lenses or refractive surgery. However, the efficacy and safety among the above are unsatisfactory.
The novel ophthalmic medicine treatment (low-dose atropine sulfate eye drops) is the only drug verified by evidence-based medicine to effectively delay the progression of myopia of children and adolescents.